Wells Fargo Starts NxStage Medical (NXTM) at Underperform; Dialysis Providers Likely Adopt Home Hemodialysis At Slow Pace
Tweet Send to a Friend
Wells Fargo initiates coverage on NxStage Medical (NASDAQ: NXTM) with a Underperform. Valuation range $15-17.
Wells analyst says, "While home ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wells analyst says, "While home ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
